To accelerate customer support, Ajinomoto Health & Nutrition North America, Inc., announces the opening of its new North American corporate headquarters. The new 55,000 square-foot headquartered opens at 250 East Devon Avenue in Itasca, Illinois.
- The new space is designed to accelerate Ajinomoto Health & Nutrition’s commitment to delivering high-quality ingredient solutions that drive value for customers.
- The headquarter features a new Customer Engagement Center with a modern, innovative culinary kitchen equipped with video and streaming capabilities for ongoing customer support, webinars and interactive demonstrations with food & beverage manufacturers and foodservice operators
- A new sensory evaluation laboratory that supports real-time analysis of ongoing product development
Major agreements and expansions by Ajinomoto Bio-Pharma are featured below:
March 2021: To boost drug product manufacturing, Ajinomoto Bio-Pharma Services announced a manufacturing agreement expansion with AstraZeneca. The agreement helps in small molecule manufacturing services proceeding in Belgium.
Dec 2020: To expand clients services Ajinomoto Bio-Pharma Services announce a strategic commercial manufacturing agreement with biotechnology company Revance Therapeutics, Inc. for the supply of DaxibotulinumtoxinA for Injection.
Aug 2020: The leading contract biopharmaceutical manufacturing company Ajinomoto Bio-Pharma Services announced the expansion of its small molecule manufacturing facility with the addition of a new production facility in Visakhapatnam, India.
June 2020: Ajinomoto Bio-Pharma Services had acquired Granules OmniChem Private Limited and acquired the remaining 50 percent stake from its joint venture partner Granules India Limited The transaction announced in August 2019 strengthens Aji Bio-Pharma’s commitment to providing its customers with access to reliable and simplified access CDMO supply chain to offer at all locations worldwide
May 2020: Ajinomoto Bio-Pharma Services had entered into a manufacturing agreement with Humanigen, Inc., for the fill finish supply of lenzilumab, currently being studied in a Phase III clinical trial in adult, hospitalized patients with COVID-19.
April 2020: Trio Pharmaceuticals, Inc., a cancer therapeutics company developing novel dual action antibody drugs, TRIObody, and novel dual action antibody drug conjugates, TRIObody Drug Conjugate (TDC) and Ajinomoto Bio-Pharma Services, announced a development collaboration agreement to evaluate AJICAP, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDCs.
About Ajinomoto Bio-Pharma
Ajinomoto Bio-Pharma Services, headquarered in Tokyo, Japan, is a leading provider of contract biopharmaceutical manufacturing and development services. It is a part of Ajinomoto Group. The company has manufacturing sites in Belgium, United States, Japan, and India. The company provides a comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates.